EVERSANA LIFE SCIENCE SERVICES supplier risk profile Q1-2026: India-concentrated pharma imports, 13 suppliers, 2 sanctions hits.
EVERSANA LIFE SCIENCE SERVICES imported 219 shipments in Q1 2026 from 13 suppliers across 5 countries, with India accounting for 93.6% of volume. The company concentrated imports on HS Chapter 30 (Pharmaceutical Products), which represented 68% of tracked shipments. Top suppliers included Zydus Lifesciences entities and Gland Pharma, all India-based.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
Two names matching OFAC and other sanctions watchlists were detected in the trade data. No suppliers show documented forced-labor exposure under the Uyghur Forced Labor Prevention Act framework.
13 distinct tier-1 suppliers in Q1 2026
| ZYDUS LIFESCIENCES FORMERLY | India | 144 |
| ZYDUS LIFESCIENCES | India | 24 |
| GLAND PHARMA | India | 14 |
| ZYDUS LIFESCIENCES FORMERLY K | India | 10 |
| INTAS PHARMACEUTICALS | India | 5 |
| CONCORD BIOTECH | India | 4 |
| CORDEN PHARMA | Portugal | 3 |
| ZYDUS ANIMAL HEALTH AND INVESTMENTS | India | 2 |
Share of Q1 2026 inbound shipments by source country
16 tier-2 + 16 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.